StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) stock

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.64+0.02 (+1.23%)

Close on Nov 17, 2026Market cap $11.80MP/E 1.1Yield –

Chemomab Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Chemomab Therapeutics's pe ratio was 0.9× on Nov 11, 2026, against 0.8× a year earlier. Over the last 5 years it ranged from 0.3× to 12.8×, with a median of 1.0×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.9×+0.4
2025Dec 31, 20250.5×−0.3
2024Dec 31, 20240.9×+0.5
2023Dec 29, 20230.4×−2.1
2022Dec 30, 20222.5×−10.3
2021Dec 31, 202112.8×+9.5
2020Jan 31, 20203.3×−0.3
2019Dec 31, 20193.6×–

More Chemomab Therapeutics figures

See a number that looks wrong?